Submit the Marketing Authorisation Application for cilta-cel in Europe
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 1 Feb 2021
- Due
- 30 Jun 2021
- Delivered
- April 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“The MAA, which is targeted for submission in the first half of 2021”
What we found
Evidence strength A What the grades mean
The company successfully submitted the Marketing Authorisation Application for cilta-cel to the European Medicines Agency in April 2021, which is within the first half of 2021 deadline.
-
A Legend Biotech Corp 20-F filed 2022-03-31
“Submission of cilta-cel’s MAA to the EMA for the treatment of RRMM was completed in April 2021.” ✓ confirmed on the page
Market reaction: the shares moved +7.3% against the S&P 500 over the three sessions around the disclosure (30 Mar 2022 to 4 Apr 2022). What this measures
Checked 25 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Regulatory submission
- Indicative materiality
- High rules
- Action
- Submit
- Deliverable
- Marketing Authorisation Application for cilta-cel
- Where
- Europe
- Language
- Aspirational (“aims”, “intends”)
- In the company’s control
- High
- Specificity
- High
- Depends on
- Regulatory
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Legend Biotech Corp? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-LEGN-022688 · Corrections policy